Cargando…

Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting

BACKGROUND: SNPs near the interferon lambda (IFNL) 3 gene are predictors for sustained virological response (SVR) in patients with chronic hepatitis C genotype (GT) 1. In addition, a dinucleotide frame shift in ss469415590 was described, which generates IFNL4. In this study, we compared the role of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiegand, Steffen B., Heidrich, Benjamin, Susser, Simone, Rogalska-Taranta, Magdalena, Petersen, Jörg, Böker, Klaus H. W., Grigorian, Natalia, Link, Ralph, Naumann, Uwe, John, Christine, Lueth, Stefan, Malfertheiner, Peter, Manns, Michael P., Wedemeyer, Heiner, Sarrazin, Christoph, Cornberg, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689517/
https://www.ncbi.nlm.nih.gov/pubmed/26699619
http://dx.doi.org/10.1371/journal.pone.0145622
_version_ 1782406857163276288
author Wiegand, Steffen B.
Heidrich, Benjamin
Susser, Simone
Rogalska-Taranta, Magdalena
Petersen, Jörg
Böker, Klaus H. W.
Grigorian, Natalia
Link, Ralph
Naumann, Uwe
John, Christine
Lueth, Stefan
Malfertheiner, Peter
Manns, Michael P.
Wedemeyer, Heiner
Sarrazin, Christoph
Cornberg, Markus
author_facet Wiegand, Steffen B.
Heidrich, Benjamin
Susser, Simone
Rogalska-Taranta, Magdalena
Petersen, Jörg
Böker, Klaus H. W.
Grigorian, Natalia
Link, Ralph
Naumann, Uwe
John, Christine
Lueth, Stefan
Malfertheiner, Peter
Manns, Michael P.
Wedemeyer, Heiner
Sarrazin, Christoph
Cornberg, Markus
author_sort Wiegand, Steffen B.
collection PubMed
description BACKGROUND: SNPs near the interferon lambda (IFNL) 3 gene are predictors for sustained virological response (SVR) in patients with chronic hepatitis C genotype (GT) 1. In addition, a dinucleotide frame shift in ss469415590 was described, which generates IFNL4. In this study, we compared the role of IFNL4 variants with IFNL3-(rs12979860) and IFNL3-(rs8099917) on response to pegylated (PEG)-IFN and Ribavirin (RBV) in patients with chronic hepatitis C GT2/3. METHODS: We recruited 1006 patients with chronic hepatitis C and GT2/3 in a large German registry. A treatment with PEG-IFN and Ribavirin was started by 959 patients. We performed genotyping of IFNL3 (rs12979860, n = 726; rs8099917, n = 687) and of IFNL4 (ss469415590; n = 631). RESULTS: Both preferable IFNL3 genotypes were associated with RVR (both p<0.0001) rather than with SVR (rs12979860: p = 0.251; rs8099917: p = 0.447). Only RVR was linked to SVR in univariate and multivariate analyzes (both p<0.001). Concordance of genotyping in patients with available serum samples and EDTA blood samples (n = 259) was more than 96% for both IFNL3 SNPs. IFNL3-(rs12979860) correlated with IFNL4: 99.2% of patients with IFNL3-(rs12979860)-CC were IFNL4-(ss469415590)-TT/TT. IFNL3-(rs12979860)-CT was linked with IFNL4-(ss469415590)-TT/ΔG (98.0%) and IFNL3-(rs12979860)-TT was associated with IFNL4-(ss469415590)-ΔG/ΔG (97.6%). CONCLUSION: IFNL3 genotyping from serum was highly efficient and can be used as an alternative if EDTA whole blood is not available. In Caucasian GT2/3 patients genotyping for INFL4-(ss469415590) does not lead to additional information for the decision-making process. Importantly, IFNL3 SNPs were not associated with SVR but with RVR. Even in the era of new direct acting antiviral (DAA) therapies, IFNL3 testing may therefore still be considered for naïve GT2/3 patients to decide if dual Peg-IFN/RBV therapy is an option in resource limited regions.
format Online
Article
Text
id pubmed-4689517
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-46895172015-12-31 Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting Wiegand, Steffen B. Heidrich, Benjamin Susser, Simone Rogalska-Taranta, Magdalena Petersen, Jörg Böker, Klaus H. W. Grigorian, Natalia Link, Ralph Naumann, Uwe John, Christine Lueth, Stefan Malfertheiner, Peter Manns, Michael P. Wedemeyer, Heiner Sarrazin, Christoph Cornberg, Markus PLoS One Research Article BACKGROUND: SNPs near the interferon lambda (IFNL) 3 gene are predictors for sustained virological response (SVR) in patients with chronic hepatitis C genotype (GT) 1. In addition, a dinucleotide frame shift in ss469415590 was described, which generates IFNL4. In this study, we compared the role of IFNL4 variants with IFNL3-(rs12979860) and IFNL3-(rs8099917) on response to pegylated (PEG)-IFN and Ribavirin (RBV) in patients with chronic hepatitis C GT2/3. METHODS: We recruited 1006 patients with chronic hepatitis C and GT2/3 in a large German registry. A treatment with PEG-IFN and Ribavirin was started by 959 patients. We performed genotyping of IFNL3 (rs12979860, n = 726; rs8099917, n = 687) and of IFNL4 (ss469415590; n = 631). RESULTS: Both preferable IFNL3 genotypes were associated with RVR (both p<0.0001) rather than with SVR (rs12979860: p = 0.251; rs8099917: p = 0.447). Only RVR was linked to SVR in univariate and multivariate analyzes (both p<0.001). Concordance of genotyping in patients with available serum samples and EDTA blood samples (n = 259) was more than 96% for both IFNL3 SNPs. IFNL3-(rs12979860) correlated with IFNL4: 99.2% of patients with IFNL3-(rs12979860)-CC were IFNL4-(ss469415590)-TT/TT. IFNL3-(rs12979860)-CT was linked with IFNL4-(ss469415590)-TT/ΔG (98.0%) and IFNL3-(rs12979860)-TT was associated with IFNL4-(ss469415590)-ΔG/ΔG (97.6%). CONCLUSION: IFNL3 genotyping from serum was highly efficient and can be used as an alternative if EDTA whole blood is not available. In Caucasian GT2/3 patients genotyping for INFL4-(ss469415590) does not lead to additional information for the decision-making process. Importantly, IFNL3 SNPs were not associated with SVR but with RVR. Even in the era of new direct acting antiviral (DAA) therapies, IFNL3 testing may therefore still be considered for naïve GT2/3 patients to decide if dual Peg-IFN/RBV therapy is an option in resource limited regions. Public Library of Science 2015-12-23 /pmc/articles/PMC4689517/ /pubmed/26699619 http://dx.doi.org/10.1371/journal.pone.0145622 Text en © 2015 Wiegand et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Wiegand, Steffen B.
Heidrich, Benjamin
Susser, Simone
Rogalska-Taranta, Magdalena
Petersen, Jörg
Böker, Klaus H. W.
Grigorian, Natalia
Link, Ralph
Naumann, Uwe
John, Christine
Lueth, Stefan
Malfertheiner, Peter
Manns, Michael P.
Wedemeyer, Heiner
Sarrazin, Christoph
Cornberg, Markus
Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting
title Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting
title_full Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting
title_fullStr Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting
title_full_unstemmed Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting
title_short Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting
title_sort performance and value of ifn-lambda3 and ifn-lambda4 genotyping in patients with chronic hepatitis c (chc) genotype 2/3 in a real world setting
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689517/
https://www.ncbi.nlm.nih.gov/pubmed/26699619
http://dx.doi.org/10.1371/journal.pone.0145622
work_keys_str_mv AT wiegandsteffenb performanceandvalueofifnlambda3andifnlambda4genotypinginpatientswithchronichepatitiscchcgenotype23inarealworldsetting
AT heidrichbenjamin performanceandvalueofifnlambda3andifnlambda4genotypinginpatientswithchronichepatitiscchcgenotype23inarealworldsetting
AT sussersimone performanceandvalueofifnlambda3andifnlambda4genotypinginpatientswithchronichepatitiscchcgenotype23inarealworldsetting
AT rogalskatarantamagdalena performanceandvalueofifnlambda3andifnlambda4genotypinginpatientswithchronichepatitiscchcgenotype23inarealworldsetting
AT petersenjorg performanceandvalueofifnlambda3andifnlambda4genotypinginpatientswithchronichepatitiscchcgenotype23inarealworldsetting
AT bokerklaushw performanceandvalueofifnlambda3andifnlambda4genotypinginpatientswithchronichepatitiscchcgenotype23inarealworldsetting
AT grigoriannatalia performanceandvalueofifnlambda3andifnlambda4genotypinginpatientswithchronichepatitiscchcgenotype23inarealworldsetting
AT linkralph performanceandvalueofifnlambda3andifnlambda4genotypinginpatientswithchronichepatitiscchcgenotype23inarealworldsetting
AT naumannuwe performanceandvalueofifnlambda3andifnlambda4genotypinginpatientswithchronichepatitiscchcgenotype23inarealworldsetting
AT johnchristine performanceandvalueofifnlambda3andifnlambda4genotypinginpatientswithchronichepatitiscchcgenotype23inarealworldsetting
AT luethstefan performanceandvalueofifnlambda3andifnlambda4genotypinginpatientswithchronichepatitiscchcgenotype23inarealworldsetting
AT malfertheinerpeter performanceandvalueofifnlambda3andifnlambda4genotypinginpatientswithchronichepatitiscchcgenotype23inarealworldsetting
AT mannsmichaelp performanceandvalueofifnlambda3andifnlambda4genotypinginpatientswithchronichepatitiscchcgenotype23inarealworldsetting
AT wedemeyerheiner performanceandvalueofifnlambda3andifnlambda4genotypinginpatientswithchronichepatitiscchcgenotype23inarealworldsetting
AT sarrazinchristoph performanceandvalueofifnlambda3andifnlambda4genotypinginpatientswithchronichepatitiscchcgenotype23inarealworldsetting
AT cornbergmarkus performanceandvalueofifnlambda3andifnlambda4genotypinginpatientswithchronichepatitiscchcgenotype23inarealworldsetting